At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
Azzalure +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure Alone or Restylane/Emervel Filler Alone
In Brief
A Phase 4 clinical trial evaluating Azzalure, Restylane/Emervel filler, and 1 other intervention for Facial Aesthetic Treatment. Completed, enrolled 61 participants across 3 sites in 2 countries.
Detailed Summary
The efficacy and safety, as well as subject satisfaction will be evaluated after single treatment with Azzalure alone or Restylane/Emervel filler alone followed by repeated combined treatment with Azzalure, Restylane/Emervel filler and Restylane Skinbooster. Subjects will be followed for up to 18 months after initial treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacial Aesthetic Treatment
CountriesFrance, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedNov 2014
Primary CompletionDec 2016
TodayJul 2026
First PostedNov 21, 2014
Enrollment StartNov 1, 2014
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.6 years ago
Interventions
Azzaluredrug
Glabellar lines
Restylane/Emervel fillerdevice
Facial tissue augmentation
Restylane Skinboosterdevice
Facial skin rejuvenation